In one of its first acts as India's new leading drugmaker, Sun Pharmaceuticals announced the beginning of the end of Ranbaxy Laboratories by removing the company from the stock markets after trading has ended on April 1.
Times have been tough for Daiichi Sankyo, and they're about to get tougher for some of the Japanese company's U.S. staffers. The drugmaker is cutting its headquarters staff by 16% on Monday, with more layoffs expected in mid-April.
AstraZeneca has decided not to go it alone on marketing Movantik. Daiichi Sankyo has signed on to help launch the constipation pill--and it's paying a pretty penny for the opportunity.
AstraZeneca announced a partnership with Daiichi Sankyo to sell its opioid-induced constipation therapy Movantik in the U.S. for a $200 million upfront fee from the Japanese drugmaker followed by sales-related payments of up to $625 million.
Two months after settlement of a $39 million Medicaid-related U.S. government suit was disclosed by Daiichi Sankyo, the details of the civil suit against the Japan-based drugmaker were laid out by the New York state's attorney general's office.
Japan's Takeda Pharmaceutical has looked at Indian companies in the vaccine space as it moves to tighten focus on that aspect of its business ahead of a Phase III trial for a dengue candidate and more broadly emerging markets as seen by a recent M&A deal in Turkey.
Daiichi Sankyo has revamped management roles and will cut reporting lines on April 1, ahead of the looming loss of its patent protection of flagship hypertension drug olmesartan (Benicar) in key markets this year to shore up its group structure.
AnGes MG has formed a new partnership with Mitsubishi Tanabe Pharma Corporation for the marketing of investigational gene therapy Collategene (beperminogene perplasmid) in Japan, ending ties with Daiichi Sankyo.
Daiichi Sankyo's got a big revenue hurdle coming up, with top treatment Benicar set to lose patent protection next year. A black-box warning on its new drug Savaysa isn't helping matters. So analysts are wondering what the company can do to plug the forthcoming sales holes.
The U.S. Federal Trade Commission said the $4 billion deal for Japan's Daiichi Sankyo to sell its troubled Ranbaxy Laboratories unit to Sun Pharmaceutical looks to be OK as long as Ranbaxy divests its generic minocycline antibacterial to Torrent Pharmaceuticals.